switching from tirzepatide to retatrutide vs. Will Retatrutide Replace Tirzepatide
Description
SeekPeptides members regularly report that switching to low dead space syringes extended their vial supply by 10-15% with no other changes
Retatrutide is a new drug for obesity that is currently being developed by Eli Lilly
NRF-2023R1A2C1007013 and RS-2024-00348330)
Why are investors betting on combination therapies like CagriSema over single-drug approaches
Larger reductions in A1c were generally seen with higher doses of SGLT2-I and amongst patients with higher baseline A1c values
[28] However, insulin resistance disrupts these regulatory effects, resulting in prolonged depolarization and excessive neuronal firing
